Bradbury, L., Barlow, S., Geoghegan, F., Hannon, R., Stuckey, S., Wass, J., . . . Duncan, E. (2012). Risedronate in adults with osteogenesis imperfecta type I: Increased bone mineral density and decreased bone turnover, but high fracture rate persists.
芝加哥风格引文Bradbury, L., S. Barlow, F. Geoghegan, R. Hannon, S. Stuckey, J. Wass, R. Russell, M. Brown, 与 E. Duncan. Risedronate in Adults with Osteogenesis Imperfecta Type I: Increased Bone Mineral Density and Decreased Bone Turnover, but High Fracture Rate Persists. 2012.
MLA引文Bradbury, L., et al. Risedronate in Adults with Osteogenesis Imperfecta Type I: Increased Bone Mineral Density and Decreased Bone Turnover, but High Fracture Rate Persists. 2012.
警告：这些引文格式不一定是100％准确.